Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,471.80 | 39.90 | 0.47% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,219.78 | 345.64 | 1.83% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,474.30 | 716.10 | -1.83% |
| NZX 50 Index | 12,879.60 | 4.78 | -0.04% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,231.00 | 39.10 | 0.48% |
| SSE Composite Index | 3,240.94 | 80.19 | 2.54% |